References
- Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. Available from: ginasthma.org
- Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046.
- Licskai C, Yang CL, Lemiere C, et al. Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context? Can J Respir Crit Care & Sleep Med. 2019; 1–4.
- Wechsler ME, Szefler SJ, Ortega VE, et al. Step-Up therapy in black children and adults with poorly controlled asthma. N Engl J Med. 2019;381(13):1227–1239. doi:10.1056/NEJMoa1905560.
- Lougheed MD, Leniere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults: executive summary. Can Respir J. 2012;19(6):e81–88. doi:10.1155/2012/214129.
- Hallas HW, Chawes BL, Rasmussen MA, et al. Airway obstruction and bronchial reactivity from age 1 month until 13 years in children with asthma: A prospective birth cohort study. PLoS Med. 2019;16(1):e1002722. doi:10.1371/journal.pmed.1002722.
- Hallas HW, Chawes BL, Arianto L, et al. Children with asthma have fixed airway obstruction through childhood unaffected by exacerbations. J Allergy Clin Immunol Pract. 2019; in press.
- Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single phe508del allele. N Engl J Med. 2019;381(19):1809–1819., doi:10.1056/NEJMoa1908639.
- Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England. 2019;394(10212):1940–1948. doi:10.1016/S0140-6736(19)32597-8.
- Canada CF. 2018. The Canadian cystic fibrosis registry 2018 annual data report. Toronto, Canada: Cystic Fibrosis Canda.
- Chatham-Stephens K, Roguski K, Jang Y et al. Characteristics of hospitalized and nonhospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury - United States, november 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1076–1080. doi:10.15585/mmwr.mm6846e1.
- Cullen KA, Gentzke AS, Sawdey MD, et al. e-Cigarette use among youth in the United States, 2019. JAMA. 2019;322(21):2095. doi:10.1001/jama.2019.18387.
- Miech RA, Patrick ME, O’Malley PM, et al. Trends in reported marijuana vaping among US adolescents, 2017–2019. JAMA. 2020;323(5):475–476.
- O’Connor MG, Griffiths A, Iyer NP, et al. Summary for Clinicians: Diagnosis of Primary Ciliary Dyskinesia. Annals ATS. 2019; 16:171–174. doi:10.1513/AnnalsATS.201810-693CME.
- Shapiro AJ, Dell SD, Gaston B, et al. Nasal nitric oxide measurement in primary ciliary dyskinesia: a technical paper on standardized testing protocols. Ann Am Thorac Soc. 2020;17(2):e1–e12.
- Davis SD, Rosenfeld M, Lee HS, et al. Primary ciliary dyskinesia: longitudinal study of lung disease by ultrastructure defect and genotype. Am J Respir Crit Care Med. 2019;199(2):190–198. doi:10.1164/rccm.201803-0548OC.
- Wang D, Fu W, Dai J. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Medicine (Baltimore. 2019;98(17):e15285. doi:10.1097/MD.0000000000015285.